Journal article
Preliminary Assessment of the Efficacy of a T-Cell–Based Influenza Vaccine, MVA-NP+M1, in Humans
Abstract
BACKGROUND: The novel influenza vaccine MVA-NP+M1 is designed to boost cross-reactive T-cell responses to internal antigens of the influenza A virus that are conserved across all subtypes, providing protection against both influenza disease and virus shedding against all influenza A viruses. Following a phase 1 clinical study that demonstrated vaccine safety and immunogenicity, a phase 2a vaccination and influenza challenge study has been …
Authors
Lillie PJ; Berthoud TK; Powell TJ; Lambe T; Mullarkey C; Spencer AJ; Hamill M; Peng Y; Blais M-E; Duncan CJA
Journal
Clinical Infectious Diseases, Vol. 55, No. 1, pp. 19–25
Publisher
Oxford University Press (OUP)
Publication Date
July 1, 2012
DOI
10.1093/cid/cis327
ISSN
1058-4838